iLumi Biomed & Life Sciences partners with leading global innovators in stem-cell and exosome science to bring clinically validated therapies into the U.S. market through disciplined, compliant commercialization pathways.
BUILT ON CLINICAL EVIDENCE · DESIGNED FOR SCALABLE ACCESS
We collaborate with select international partners developing allogeneic stem-cell, secretome, and exosome platforms with robust pre-clinical and clinical data.
iLumi Biomed architects commercialization pathways that align scientific value, regulatory realities, and the operating models of major distributors, hospital networks, and specialty channels.
Our team manages the business development pipeline—from introductions and diligence support through to finalized U.S. licensing or distribution structures.